Protara Therapeutics (TARA) Other Gross PP&E Adjustments (2016 - 2026)
Protara Therapeutics' Other Gross PP&E Adjustments history spans 14 years, with the latest figure at -$2.9 million for Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 27.58% to -$2.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.9 million through Mar 2026, up 27.58% year-over-year, with the annual reading at -$5.9 million for FY2025, 30.21% up from the prior year.
- Other Gross PP&E Adjustments came in at -$2.9 million for Q1 2026, up from -$5.9 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$2.9 million in Q1 2026 to a low of -$8.5 million in Q4 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$5.8 million (2023), against an average of -$5.6 million.
- Year-over-year, Other Gross PP&E Adjustments fell 13.91% in 2023 and then soared 30.21% in 2025.
- Protara Therapeutics' Other Gross PP&E Adjustments stood at -$6.7 million in 2022, then decreased by 13.91% to -$7.6 million in 2023, then decreased by 11.25% to -$8.5 million in 2024, then skyrocketed by 30.21% to -$5.9 million in 2025, then soared by 51.06% to -$2.9 million in 2026.
- Per Business Quant, the three most recent readings for TARA's Other Gross PP&E Adjustments are -$2.9 million (Q1 2026), -$5.9 million (Q4 2025), and -$3.5 million (Q3 2025).